Georgina V. Long

Georgina V. Long

Sydney, NSW 2050, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 619 publications

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026

Analytical Performance of the Avida Duo Assay for Simultaneous Mutation and Methylation Profiling in Circulating Cell-Free DNA.

Analytical Performance of the Avida Duo Assay for Simultaneous Mutation and Methylation Profiling in Circulating Cell-Free DNA.

Journal: Cancers
Published: May 23, 2026

Immunotherapy for early-stage cutaneous squamous cell carcinoma.

Immunotherapy for early-stage cutaneous squamous cell carcinoma.

Journal: Journal for immunotherapy of cancer
Published: May 14, 2026

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

Journal: European journal of cancer (Oxford, England : 1990)
Published: May 06, 2026

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2026

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal: Journal for immunotherapy of cancer
Published: March 31, 2026

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

Journal: JCO precision oncology
Published: March 12, 2026

Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma.

Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma.

Journal: Oncoimmunology
Published: March 11, 2026

Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.

Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.

Journal: JAMA network open
Published: February 17, 2026

ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma.

ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma.

Journal: Annals of surgical oncology
Published: January 23, 2026

Translating ctDNA into cutaneous melanoma care: An international expert survey.

Translating ctDNA into cutaneous melanoma care: An international expert survey.

Journal: European journal of cancer (Oxford, England : 1990)
Published: January 13, 2026
Showing 1-12 of 619

Last Updated: 09/26/2026